By combining BMI and the levels of IGFBP2 and IGFBP3 in assessment of breast cancer patient survival, the authors demonstrated that without correction for BMI neither IGFBP2 nor IGFBP3 were predictive of overall survival, whereas inclusion of BMI identified that higher IGFBP2 levels to be a beneficial prognosticator. This evidence concerns the gene IGFBP2 and breast cancer.